Key insights into MSCs for aGvHD – the current clinical trial landscape
This educational resource is independently supported by Medac. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.
Mesenchymal stromal cells (MSCs) have emerged as a potential therapy option in patients with steroid-refractory graft-versus-host disease (SR-GvHD).1 MSCs do not express human leukocyte antigen class II and can therefore be administered without the need for matching, giving them a distinct advantage over other cellular therapies.
The GvHD Hub spoke to Robert Zeiser, Medical…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.